- Home
- NBN vs ABUS Comparison
NBN vs ABUS Comparison
Compare NBN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBN
- ABUS
- Stock Information
- Founded
- NBN 1872
- ABUS 2005
- Country
- NBN United States
- ABUS United States
- Employees
- NBN N/A
- ABUS N/A
- Industry
- NBN Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- NBN Finance
- ABUS Health Care
- Exchange
- NBN Nasdaq
- ABUS Nasdaq
- Market Cap
- NBN 853.5M
- ABUS 711.2M
- IPO Year
- NBN N/A
- ABUS N/A
- Fundamental
- Price
- NBN $109.01
- ABUS $4.43
- Analyst Decision
- NBN Buy
- ABUS Strong Buy
- Analyst Count
- NBN 2
- ABUS 2
- Target Price
- NBN $97.50
- ABUS $5.00
- AVG Volume (30 Days)
- NBN 66.4K
- ABUS 1.6M
- Earning Date
- NBN 10-28-2025
- ABUS 11-05-2025
- Dividend Yield
- NBN 0.04%
- ABUS N/A
- EPS Growth
- NBN 32.98
- ABUS N/A
- EPS
- NBN 10.08
- ABUS N/A
- Revenue
- NBN $204,086,000.00
- ABUS $15,416,000.00
- Revenue This Year
- NBN $17.75
- ABUS $138.02
- Revenue Next Year
- NBN $9.91
- ABUS N/A
- P/E Ratio
- NBN $10.78
- ABUS N/A
- Revenue Growth
- NBN 33.67
- ABUS 53.23
- 52 Week Low
- NBN $68.89
- ABUS $2.71
- 52 Week High
- NBN $112.22
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- NBN 57.91
- ABUS 63.83
- Support Level
- NBN $107.94
- ABUS $4.37
- Resistance Level
- NBN $111.50
- ABUS $5.10
- Average True Range (ATR)
- NBN 2.37
- ABUS 0.26
- MACD
- NBN -0.59
- ABUS 0.03
- Stochastic Oscillator
- NBN 28.03
- ABUS 55.33
About NBN Northeast Bank
Northeast Bank provides banking and financial services to individual and corporate customers in the US. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived primarily from interest and dividends from the bank.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.